Short and long-term effectiveness and safety of vedolizumab in inflammatory bowel disease: results from the ENEIDA registry-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Short and long-term effectiveness and safety of vedolizumab in inflammatory bowel disease: results from the ENEIDA registry

Published:2018-10 Issue:8 Volume:48 Page:839-851
ISSN:0269-2813
Container-title:Alimentary Pharmacology & Therapeutics
language:en
Short-container-title:Aliment Pharmacol Ther

Author:

Chaparro María¹^ORCID,Garre Ana¹,Ricart Elena²,Iborra Marisa³^ORCID,Mesonero Francisco¹,Vera Isabel¹,Riestra Sabino⁴^ORCID,García-Sánchez Valle⁵,Luisa De Castro M.⁶,Martin-Cardona Albert²^ORCID,Aldeguer Xavier⁷,Mínguez Miguel³^ORCID,de-Acosta Manuel Barreiro⁸,Rivero Montserrat⁹,Muñoz Fernando¹⁰,Andreu Montserrat²,Bargalló Ana²,González-Muñoza Carlos²,Pérez Calle Jose L.¹,García-Sepulcre Mariana Fe¹¹,Bermejo Fernando¹,Huguet Jose Maria³^ORCID,Cabriada José L.¹²^ORCID,Gutiérrez Ana¹¹,Mañosa Míriam²^ORCID,Villoria Albert²,Carbajo Ana Y.¹³,Lorente Rufo¹⁴,García-López Santiago¹⁵,Piqueras Marta²^ORCID,Hinojosa Esther³,Arajol Clàudia²^ORCID,Sicilia Beatriz¹⁶,Conesa Ana Macho¹³,Sainz Empar¹⁷,Almela Pedro¹⁸,Llaó Jordina¹⁹,Roncero Oscar¹⁴,Camo Patricia²⁰,Taxonera Carlos¹,Domselaar Manuel Van¹,Pajares Ramón¹,Legido Jesús²¹,Madrigal Rosa²²,Lucendo Alfredo J.¹⁴^ORCID,Alcaín Guillermo²³,Doménech Eugeni²⁴^ORCID,Gisbert Javier P.¹^ORCID,

Affiliation:

1. Madrid Spain

2. Barcelona Spain

3. Valencia Spain

4. Asturias Spain

5. Córdoba Spain

6. Vigo Spain

7. Gerona Spain

8. Santiago de Compostela Spain

9. Santander Spain

10. Salamanca Spain

11. Alicante Spain

12. Vizcaya Spain

13. Valladolid Spain

14. Ciudad Real Spain

15. Zaragoza Spain

16. Burgos Spain

17. Lleida Spain

18. Castellón Spain

19. Manresa Spain

20. Huesca Spain

21. Segovia Spain

22. Palencia Spain

23. Málaga Spain

24. Badalona Spain

Funder

Takeda Pharmaceutical Company

Instituto de Salud Carlos III

Publisher

Wiley

Subject

Pharmacology (medical),Gastroenterology,Hepatology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/apt.14930/fullpdf

Reference30 articles.

1. Loss of response and requirement of infliximab dose intensification in Crohn's disease: a review;Gisbert;Am J Gastroenterol,2009

2. Intensification of infliximab therapy in Crohn's disease: efficacy and safety;Chaparro;J Crohns Colitis,2012

3. Long-term durability of infliximab treatment in Crohn's disease and efficacy of dose “escalation” in patients losing response;Chaparro;J Clin Gastroenterol,2011

4. The binding specificity and selective antagonism of vedolizumab, an anti-alpha4beta7 integrin therapeutic antibody in development for inflammatory bowel diseases;Soler;J Pharmacol Exp Ther,2009

5. Vedolizumab as induction and maintenance therapy for ulcerative colitis;Feagan;N Engl J Med,2013

Cited by 72 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Obesity, Sarcopenia and Myosteatosis: Impact on Clinical Outcomes in the Operative Management of Crohn’s Disease;Inflammatory Bowel Diseases;2023-10-20

2. Algorithmic identification of treatment-emergent adverse events from clinical notes using large language models: a pilot study in inflammatory bowel disease;2023-09-08

3. Clinical profiles and outcomes in patients with ulcerative colitis receiving standard and higher-than-standard doses of vedolizumab: findings from a real-world study in Europe;Current Medical Research and Opinion;2023-08-28

4. Safety, Effectiveness, and Treatment Persistence of Subcutaneous Vedolizumab in IBD: A Multicenter Study From the United Kingdom;Inflammatory Bowel Diseases;2023-08-21

5. Anti-TNF Agents and New Biological Agents (Vedolizumab and Ustekinumab) in the Prevention and Treatment of Postoperative Recurrence After Surgery in Crohn’s Disease;Drugs;2023-07-28

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3